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Abstract: Background: Previous research indicates that total cholesterol levels increase
with age during young adulthood and middle age and decline with age later in life.
This is attributed to changes in diet, body composition, medication use, physical activity,
and hormone levels. In the current study we utilized data from the Framingham Heart
Study Original Cohort to determine if variations in apolipoprotein E (APOE), a gene involved
in regulating cholesterol homeostasis, influence trajectories of total cholesterol,
HDL cholesterol, and total: HDL cholesterol ratio from midlife through late life.
Methods: Cholesterol trajectories from midlife through late life were modeled using
generalized additive mixed models and mixed-effects regression models. Results: APOE e2+
subjects had lower total cholesterol levels, higher HDL cholesterol levels, and lower total:
HDL cholesterol ratios from midlife to late life compared to APOE e3 and APOE e4+
subjects. Statistically significant differences in life span cholesterol trajectories

Int. J. Environ. Res. Public Health 2014, 11

10664

according to gender and use of cholesterol-lowering medications were also detected.
Conclusion: The findings from this research provide evidence that variations in APOE modify
trajectories of serum cholesterol from midlife to late life. In order to efficiently modify
cholesterol through the life span, it is important to take into account APOE allele status.
Keywords: cholesterol; life span; aging; Apolipoprotein E

1. Introduction
There is a negative perception associated with cholesterol among the general public due to the
frequently observed relationship between high cholesterol and adverse health events, such as heart
attack and stroke [1]. This perception that cholesterol only has a negative impact on health is
somewhat misguided because cholesterol is an essential molecule for healthy functioning of the human
body. The liver is the primary source of cholesterol for the body [2], but animal-based food products
such as meat, eggs, and cheese are also significant sources of cholesterol [3]. Cholesterol is necessary
for maintaining the structural integrity of cell membranes [4] and is a precursor for hormones like
testosterone and estrogen and vitamin D, as well as bile salts, which aid in digestion [5]. Cholesterol is
transported in the bloodstream by combining with specialized proteins to form lipoproteins. Low density
lipoproteins (LDL) and very-low density lipoproteins (VLDL) are more buoyant because they contain
more cholesterol in relation to protein. LDL transports cholesterol from the liver through the
bloodstream to be used by cells throughout the body [6], and VLDL transports triglycerides and
cholesterol to cells to be used for energy [7]. The low-density lipoprotein receptor (LDLR) is
responsible for regulating the absorption of cholesterol and triglycerides into the cell [8]. Once VLDL
has transported the triglycerides to a cell, it is converted to LDL [9]. High density lipoproteins (HDL)
contain more protein in relation to cholesterol and as a result travel more efficiently through the blood
stream than LDL and VLDL. HDL cholesterol is commonly referred to as “good cholesterol” because
of its role in reverse cholesterol transport in which excess cholesterol is carried back to the liver where
it is broken down and excreted from the body by being converted into bile [10,11]. Total cholesterol is
the sum of HDL, LDL, and VLDL cholesterol. The ratio of total cholesterol to HDL cholesterol is a
commonly used measure of cholesterol in clinical settings because this measure has been found to be
more accurate in predicting coronary heart disease than either total cholesterol levels or LDL
cholesterol levels [12–14]. However, the accuracy of this ratio is questionable at the extreme ends of
the total and LDL cholesterol distributions [15]. The National Cholesterol Education Program
recommends that for adults, total cholesterol levels should not exceed 200 mg/dL, LDL cholesterol
levels should not exceed 100 mg/dL; HDL cholesterol levels should be at least 40 mg/dL for men and
50 mg/dL for women [16]. Based on data from the National Health and Nutrition Examination Survey,
the percentage of adults between the ages of 40 and 74 with high LDL cholesterol levels has declined
from 59% between 1976–1980 to 27% between 2007–2010 [17]. This decline is due largely to the
increasing trend in the number of Americans who have been prescribed cholesterol-lowering
medications during the same time period [17]. Maintaining healthy levels of cholesterol is still a
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significant public health concern because adults with high LDL cholesterol levels or low HDL
cholesterol levels are at a substantial risk for cardiovascular diseases [18].
1.1. Age Related Changes to Cholesterol
Previous research indicates that total cholesterol levels and LDL cholesterol levels increase with
age among young and middle age adults and decline with age later in life [19–24]. The relationship
between age and HDL cholesterol levels is controversial, with some studies supporting a decrease in
HDL cholesterol levels with age, while others have reported minimal change and even an increase in
HDL cholesterol levels with age [22,23,25]. There are several factors that contribute to the age related
changes in cholesterol. First, LDLR activity tends to decrease with age leading to an increase in
circulating LDL as less LDL is absorbed by cells [26]. A decrease in the conversion of cholesterol to
bile acid with advancing age also contributes to an increase in serum cholesterol with age [27].
The most consistent predictors across studies for an increase in total cholesterol levels among young
and middle aged adults are consuming a high fat diet [28,29] and weight gain [20,30]. The decline in
total cholesterol levels among older adults has been observed to coincide with dietary changes [24],
weight loss, a decrease in body fat, and the use of statins and other cholesterol-lowering medications [19].
Hormonal changes also contribute to the age related changes in cholesterol observed among women.
Young and middle-aged women tend to have lower total cholesterol and higher HDL cholesterol
compared to men, but these gender differences become less apparent with increasing age [31].
As women age, total cholesterol levels increase and HDL cholesterol levels may decrease due to a
decline in estrogen production preceding menopause [32,33]. Estrogen regulates cholesterol
biosynthesis [34] and estrogen replacement therapy is an effective approach for maintaining a healthy
cholesterol profile for women who are approaching or experiencing menopause [35,36]. Measures of
socioeconomic status, health behaviors, and health characteristics are also associated with total
cholesterol levels and HDL cholesterol levels. Low education and low income are associated with poor
cardiovascular health [37] and higher total cholesterol [37,38]. These same studies report that adults
with high educational attainment and high income also have higher HDL cholesterol levels [37,38].
Also, adults who smoke have lower HDL cholesterol levels compared to non-smokers [39].
Finally, hypertensive adults have higher total cholesterol levels and lower HDL cholesterol levels
compared to adults without hypertension [40].
Previous studies have reported that the effect of age on cholesterol remains significant even after
adjusting for changes in diet, physical activity and the use of statins and other lipid lowering
medications [21] suggesting that additional factors contribute to the age related changes in cholesterol.
Among these potential factors, we explore here variations in apolipoprotein E (APOE), a gene involved in
regulating cholesterol homeostasis.
1.2. Apolipoprotein E and Cholesterol
Several genes encode proteins that are critical to the absorption, transport, and excretion of
cholesterol [41,42]. One such gene is APOE. APOE is located on the long arm of chromosome
19 (19q13.2) and includes three common alleles (e2, e3, and e4) resulting in six distinct genotypes.
The allelic frequency of the APOE e2, e3, and e4 alleles among Caucasians is approximately 7%,
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78%, and 15%, respectively [43]. The apoE protein is one of several proteins that transport cholesterol
and triglycerides through the bloodstream as VLDL and is also involved in the conversion of VLDL to
LDL cholesterol and the absorption of cholesterol by the small intestines [44]. While there is debate on
if APOE genotypes effect the rate of cholesterol absorption [45,46] adults with the APOE e3/e3
genotype tend to have lower total cholesterol than adults with either the APOE e3/e4 or APOE e4/e4
genotypes, but higher total cholesterol compared to adults with either the APOE e2/e4, e2/e3 or e2/e2
genotypes [47–49]. When environmental factors such as high body mass index (BMI), consuming a
high calorie diet and high blood sugar levels are also present, adults with the APOE e2/e2 genotype are
at an increased risk for type III hyperlipidemia [50], a condition characterized by abnormally
high bloodstream concentrations of chylomicrons, which are another lipoprotein that transports
triglycerides to cells [7].
The observed relationship between APOE genotypes and serum cholesterol has led to considerable
research on the relationship between APOE polymorphisms and diseases associated with high
cholesterol. The APOE e4 allele is associated with an increased risk for cardiovascular diseases [51],
including stroke [52], and coronary heart disease [53]. The APOE e4 allele is also an established risk
factor for dementia, in particular Alzheimer’s disease (AD) [54], whereas as the APOE e2 allele is
associated with a decreased risk for AD relative to the APOE e3 allele [55]. The consistent association
between AD and APOE has contributed to research on the relationship between serum cholesterol
levels and AD risk. Interestingly, the association between serum cholesterol and AD appears to depend
upon the age in which cholesterol is measured. High total cholesterol levels during middle age are
associated with an increased risk for AD during old age [56], but older adults with AD tend to have
lower total cholesterol compared to non-demented older adults [57] and high cholesterol during old
age is associated with a decreased risk for AD [58]. Further, Stewart et al. [59] observed in the
Honolulu-Asia Aging Study that men who developed dementia exhibited a decline in total cholesterol,
on average, 15 years before dementia diagnosis and maintained lower total cholesterol levels during
this 15 year period than men who did not develop dementia. A plausible hypothesis for apparent age
dependent relationship between serum cholesterol and dementia is that there are distinct differences in
serum cholesterol levels from midlife through late life according to APOE allele status. This justifies
research to examine if trajectories of serum cholesterol from midlife through late life differ according
to APOE allele status.
The apoE alleles clearly modulate cholesterol homeostasis as indicated by the differences in
cholesterol concentrations among adults according to APOE genotypes. However, it is not clear how
APOE polymorphisms influence the longitudinal trajectories of cholesterol from midlife through late
life. Accordingly, the purpose of this study is to characterize the longitudinal trajectories of total
cholesterol, HDL cholesterol, and total: HDL cholesterol ratio according to APOE e2, e3, and e4 allele
status utilizing data from the Framingham Heart Study (FHS) Original Cohort.
2. Methods
2.1. Framingham Heart Study: Original Cohort
The FHS is an ongoing prospective cohort study of residents from Framingham Massachusetts,
United States, created with the goal of generating knowledge on the onset and progression of
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cardiovascular diseases, as well as genetic and environmental risk factors for these diseases.
The FHS Original Cohort was initiated in 1948 and includes adults who did not have a cardiovascular
disease upon entry into the study [60]. A total of 5079 subjects between the ages of 28 and 74
(mean age 44.2 years) completed a baseline clinical examination between 1948 and 1953.
Thirty clinical examinations have been completed since 1948, and 141 subjects (mean age 92,
range 88–102) attended the thirtieth clinical exam, which concluded in 2010. During each wave of data
collection, subjects received an extensive physical examination, which included non-invasive tests
(e.g., body composition, x-ray, and pulmonary function), lab tests (e.g., lipid and hormone levels),
and a health history questionnaire to assess health behavior and the onset of any health conditions
since the previous wave of data collection. DNA collection from living members of the FHS Original
Cohort began in the 1980s and APOE genotype data is available for a total of 663 subjects.
For the purposes of the current study, subjects were classified as APOE e2+ (e2/e2 or e2/e3 genotype),
APOE e3 (e3/e3 genotype), or APOE e4+ (e3/e4 or e4/e4). Subjects with the APOE e2/e4 genotype
(n = 11) were excluded from the final sample due to the low sample size and conflicting influence that
the APOE e2 and APOE e4 alleles have on cholesterol levels. Because the purpose of this study was to
examine cholesterol trajectories beginning in midlife, nine subjects that were not between 30
and 55 years of age during the first clinical examination were excluded from the final sample.
Finally, all subjects had two or more repeated measures for total cholesterol; 21 subjects who had
fewer than two consecutive repeated measures for HDL cholesterol were excluded from the final
sample. The final sample included 596 subjects.
2.2. Measures of Serum Cholesterol
Measures for total cholesterol and HDL cholesterol were collected from subjects of the FHS
Original Cohort using standard laboratory procedures [61]. Fasting measures for total cholesterol were
collected during twenty clinical examinations (1–11, 13–15, 20, 22, 24–27) and measures of HDL
cholesterol were collected during ten clinical examinations (9–11, 15, 20, 22, 24–27). The ratio of total:
HDL cholesterol was calculated by dividing the measure of total cholesterol by the measure of
HDL cholesterol. The distributions for total: HDL ratios were highly right skewed and were
normalized by log transformation. Serum LDL cholesterol was directly measured in the FHS during
three clinical examinations (9–11). The Friedewald equation [62] can be used to estimate
LDL cholesterol levels based on total cholesterol, HDL cholesterol, and triglyceride levels
(LDL = total – HDL – triglycerides/5). This equation, however, should not be used when triglyceride
levels are greater than 400 mg/dL [62] and underestimates LDL cholesterol levels when triglyceride
levels exceed 200 mg/dL [63]. Triglyceride levels were measured during nine clinical examinations
(7–11, 24–27), but for any given clinical examination over 25 percent of subjects included in the final
sample did not have a recorded triglyceride measure. Furthermore, over 13 percent of subjects in
each clinical examination had triglyceride levels over 200 mg/dL. In light of these limitations,
LDL cholesterol levels were not included in this study.
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2.3. Statistical Analysis
The trajectories of total cholesterol levels, HDL cholesterol levels, and total: HDL cholesterol ratios
from midlife through late life according to APOE allele status were modeled using generalized additive
mixed models [64] (GAMM) implemented using the gamm4 package[65] in R version 3.1 GAMM are
semi-parametric models that utilize a data-driven approach to model a non-linear relationship between
dependent and independent variables as opposed to restriction to fully parametric polynomial terms.
The general form of the GAMM used for this study is:
=

where

+

(

= 2+) +

(

= 3) +

(

= 4+) +

+

is the value of cholesterol for the ith subject during the jth observation given the covariates

included in the model (see Covariates), and bi is a subject-specific random effect that allows for the
baseline value of cholesterol to vary for each subject. Xi is a k-length vector comprising the k timeinvariant covariates of subject i and is a k-length vector of the fixed effects for the corresponding k
covariates; xij is the age of the ith subject during the jth observation; se2, se3, and se4 are the allelespecific smoothing functions for subjects who were APOE e2+, e3, and e4+, respectively, APOEi is
the allele status for the ith subject; and I( ) is an indicator function equal to 1 when x is true and 0
otherwise. The term
is the within-subject error term, which is the difference between the observed
measure of cholesterol and the expected measure of cholesterol based on the model.
The terms bi and
are assumed to be independent and randomly distributed with mean zero and
variances of
and , respectively. The inclusion of three different smoothing functions (se2, se3,
and se4) allows for the trajectories of cholesterol to vary according to APOE allele status.
The smoothing function (thin plate regression splines) models the potentially non-linear trajectory
of cholesterol with advancing age. An advantage of the thin plate regression spline function over other
smoothing functions is that the number and placement of knots that control the flexibility of the model
do not need to be specified [66]. The more knots included in the model, the better the model will fit the
data, but this is at the risk of over fitting the data. Concerns of over fitting are addressed by adding a
second derivative function on the penalty to the least squares fitting approach [66] providing a tradeoff
between model fit and model smoothness [67]. A detailed description of how the thin plate regression
spline balances the flexibility and fit of the model has been previously provided [67].
Briefly, the thin plate regression spline estimates the smoothing function si by identifying the function
that minimizes the equation described below. is the smoothing term that reflects the flexibility
of the model
| − f| +
( )
where | − f| can be interpreted as the observed data values minus the values predicted from the
model, squared;
( ) is the penalty function that controls f; and is the smoothing parameter that
controls the balance between the model fit and the smoothness of f.
The estimated trajectories of total cholesterol levels, HDL cholesterol levels, and total: HDL cholesterol
ratio were plotted along with point-wise 95% confidence intervals constructed by calculating the upper
and lower bounds for each predicted measure of total cholesterol levels, HDL cholesterol levels,
and total: HDL cholesterol ratio. This allowed for the trajectories of total cholesterol levels,
HDL cholesterol levels and total: HDL ratio according to APOE allele status to be visually examined.
The plots of the estimated trajectories for the adjusted models were obtained by predicting the average
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values of serum cholesterol based on age and the values of the covariates included in the model.
These trajectories represent the average trajectory of serum cholesterol according to APOE allele status
controlling for the effects of the covariates. The degree to which the trajectories of cholesterol
departed from linearity is reflected by the effective degrees of freedom (EDF) of the smoothing
parameter ( ) [68]. The EDF provides a measure of a model’s flexibility and a smooth term with
x EDF can be interpreted as an x degree polynomial term. An EDF of 1 indicates that the trajectory is
linear and increasing values of EDF indicate greater degrees of non-linearity. Including the
EDF values, aids in the interpretation of the estimated trajectories by providing a value for the
smoothing function of the trajectory. Also, the potential effects of covariates on the estimated trajectories
can be assessed based on the changes to the EDF values as covariates are added to the models.
GAMM allow for between group comparisons to be made based on the 95% confidence intervals of
each measure of serum cholesterol, but a challenge when using this method is assessing statistically
significant differences in the estimated trajectories of serum cholesterol according to APOE allele
status or other variable of interest. Since the EDF of the smooth term can be interpreted as an x degree
polynomial, we used the EDF values obtained from the GAMM as estimates for polynomial terms in
mixed-effects regression models [69]. This allowed us to produce evidence for statistically significant
differences for the trajectories and aided in the interpretation of the estimated trajectories of serum
cholesterol levels presented in the Figures 1–4.
2.4. Covariates
Data for several potential confounding variables were collected during each clinical examination
using standard laboratory procedures and a medical history interview. An overview of the covariates
included in the present analysis and the years in which they were collected is provided in Table 1.
Covariates were selected according to those included in previous studies that examined longitudinal
changes in serum cholesterol levels [20,21]. Also, certain covariates that have been identified as
having an effect on serum cholesterol levels were included even if the covariate had not been shown to
be associated with APOE allele status. Age during the baseline clinical examination was included as a
covariate to differentiate between-subject from within-subject variability for the change in serum
cholesterol with age. Educational attainment was initially recorded according to the following
categories: (1) none, (2) fourth grade or less, (3) fifth, sixth or seventh grade, (4) completed grade
school, (5) some high school, (6) graduated high school, (7) some college, (8) college graduate or
(9) post graduate. For the purposes of this study, educational attainment was dichotomized according
to receiving a high school (HS) degree (<HS or >HS). From clinical examination 7 through 21,
subjects were asked if they were using cholesterol-lowering drugs, and it was not until clinical
examination 22 that subjects were asked which type of medication they used (resins, niacin, fibrates,
or statins). Since specific cholesterol-lowering medications were not assessed until the 22nd clinical
examination, subjects were dichotomized as having reported ever using a cholesterol-lowering
medication (yes/no). The age in which subjects first started using cholesterol-lowering medications
was included as a covariate in a subsequent analysis to account for differences in the timing in which
subjects started taking cholesterol-lowering medications. Also, an analysis limited to only women that
controlled for the use of supplemental estrogen and age of menopause was also conducted.
During the 1st through 14th clinical examinations, women were asked the age in which menses had
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stopped for one year or more and the cause of cessation (natural, surgical, or other). The average age
of menopause was 47.5 years (SD = 6.0, range = 23–57 years), but significant differences in the
average age of menopause according to cause of cessation were detected (natural (n = 242) 49.9 years,
SD = 3.4; surgery (n = 108) 42.3 years, SD = 7.1; other (n = 3) 41.7 years, SD = 7.6; F-value = 92.9,
p < 0.01). Therefore, the cause of cessation of menses was included as a covariate in this analysis.
The use of supplemental estrogen (oral, patch, or cream) was assessed during clinical exams 17–27.
Subjects were dichotomized as having reported ever using supplemental estrogen (yes/no).
Subjects were asked during clinical exams 2, 4, 7–15, and 17 if they were consuming a diet meant to
control high cholesterol, diabetes, hypertension, weight, or other low calorie diet. Subjects were
dichotomized as reported ever consuming a restricted diet (yes/no). Systolic blood pressure, diastolic
blood pressure, height (inches) and weight (pounds) were collected during each clinical examination.
Smoking status was assessed during clinical exams 4–27. Blood sugar levels were measured during
clinical exams 1, 2, 4, 6, 8–23, 26 and 27. Body mass index (BMI) was calculated as (weight/height2)
× 703. Smoking status [70], blood pressure [71], BMI [72] and blood sugar [73] have been observed to
change with age. Therefore, we included measures for these covariates during the 1st clinical examination
(representing midlife) and 15th clinical examination (representing late life). This accounted for potential
changes in these variables from midlife to late life and limited the number of covariates included in each
model since these variables were measured during almost all clinical examinations. The 1st clinical
examination represented midlife because only subjects between the ages of 30–55 during this examination
were included in the final sample. Smoking status during the 4th clinical examination was included as a
covariate since smoking was not assessed during the 1st through 3rd clinical examinations.
Only 12 subjects (2.0% of final sample) did not attend the 4th clinical examination. The average age of
the subjects who did attend the 4th clinical examination was 44.3 years (range = 35–61). The 15th clinical
examination was selected for late life because the average age of the final sample was 66.3 years
(range = 58–83 years). These cut offs for midlife and late life are consistent with those used in previous
studies [74,75]. A total of 570 subjects (95.6% of final sample) attended the 15th clinical examination.
Covariate values for the 14th or 16th clinical examination were used for subjects who did not attend the
15th clinical examination.
3. Results
3.1. Description of Framingham Heart Study: Original Cohort
The descriptive characteristics of subjects of included in the final sample are provided in Table 2.
The final sample included a total of 596 subjects, of which 61 were APOE e2+ (n = 4 e2/e2; n = 57
e2/e3), 406 were APOE e3, and 129 were APOE e4+ (n = 5 e4/e4; n = 124 e3/e4). The final sample
was predominantly female and the majority of subjects had a high school degree or less. There were no
statistically significant differences in APOE allele status according to any of the characteristics listed
in Table 2. Compared to women, men were more likely to be current smokers during midlife
(men = 149 (65.1%), women = 135 (38.8%), = 44.4, p < 0.01) and late life (men = 79 (33.3%),
women = 74 (21.3%), = 56.6, p <0.01), had high average BMI during midlife (men = 25.7 kg/m2,
women = 24.7 kg/m2, t-value = −3.4, p < 0.01) and late life (men = 27.2 kg/m2,women = 26.5 kg/m2,
t-value = –2.2, p = 0.03), higher average blood sugar during late life, but not midlife, (men = 95.7 mg/dL,
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women = 91.7, t-value = –2.0, p < 0.05), higher average systolic blood pressure during midlife,
but not late life, (men = 131.5 mmHg, women = 126.3 mmHg, t-value = −4.0, p < 0.01), and higher
average diastolic blood pressure during midlife (men = 82.6 mmHg, women = 80.3 mmHg,
t-value = −2.6, p = 0.01 ) and late life (men = 78.1 mmHg, women = 75.5 mmHg, t-value = –3.1, p = 0.02).
3.2. Total Cholesterol Stratified by APOE Allele Status
The unadjusted and adjusted trajectories of total cholesterol, HDL cholesterol, and total:
HDL cholesterol ratio, according to APOE allele status, are presented in Figure 1. Solid lines
represent the mean measures of serum cholesterol according to APOE status and the shaded regions
represent the point-wise 95% confidence intervals for each estimated measure. The degree of
non-linearity for the trajectories as reflected by the estimated EDF of the smoothing term, and the
model fit by adjusted R2, which is interpreted as the proportion of total variance explained by the
model with an adjustment for model complexity, are presented in Table 3. According to visual
inspection, there were little to no differences in the unadjusted mean measures of total cholesterol,
HDL cholesterol, and total: HDL cholesterol ratio as indicated by the overlap of the 95% confidence
intervals. Inclusion of covariates to the models noticeably reduced the variability in estimated
cholesterol trajectories as indicated by the 95% confidence intervals for each measure of cholesterol;
however, trajectories of cholesterol did not substantially change once covariates were added to the
models as indicated by the consistent EDF values of the smooth terms. The dramatic reduction in the
95% confidence intervals for the adjusted models compared to the unadjusted models suggests that
several factors account for the variability in serum cholesterol levels. Including covariates reduces the
error variance of the model, which reduces the variability of the estimates of serum cholesterol.
Total cholesterol trajectories for APOE e2+, e3, and e4+ subjects all followed similar non-linear
trends based on the EDF values (Table 3. Significant differences according to APOE allele status were
detected after controlling for the effects of age, gender, educational attainment, smoking status, BMI,
systolic and diastolic blood pressure, blood sugar levels, restricted diet, and use of cholesterol-lowering
medications (Figure 1. Subjects who were APOE e2+ maintained consistently lower total cholesterol
from midlife through late life compared to APOE e3 and APOE e4+ subjects. APOE e3 and APOE e4+
subjects had similar trajectories for total cholesterol until 50 years of age, at which point APOE e3
subjects displayed a decline in total cholesterol while total cholesterol in APOE e4+ subjects continued
to increase until 60 years of age. The greatest difference in total cholesterol between APOE e3 and
APOE e4+ subjects was at 60 years of age and the differences in total cholesterol between these two
groups became less apparent with advancing age. A mixed-effects regression model that included
linear through 7th order polynomial terms for age detected statistically significant differences
in the interaction terms from APOE allele status and quadratic (F-value = 4.7, p < 0.01) and quartic
(F-value = 8.2, p < 0.01) terms, while the cubic term approached statistical significance
(F-value = 2.9, p = 0.06).
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Table 1. Assessment of total cholesterol, HDL cholesterol, and selected covariates from the Framingham Heart Study Original Cohort.
Measure

Measure Collected

Age

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

Weight

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

Height

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*

*
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Notes: Subjects were evaluated every 2 years beginning in 1948. Clinical examination 27 was completed in 2003.
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Figure 1. Cholesterol trajectories stratified according to APOE e2+, e3, and e4+ allele status.

Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes.
Unadjusted cholesterol trajectories (row one) only included APOE allele status. Adjusted cholesterol trajectories (row two) controlled for the effects of age gender,
educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, body mass index, restricted diet, and use of cholesterol-lowering medications.
Unadjusted trajectories n = 596; adjusted trajectories n = 555. Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E.
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Figure 2. Cholesterol trajectories stratified according to history of using cholesterol-lowering medications, and APOE allele status adjusting
for age of first using cholesterol-lowering medications.

Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes.
Cholesterol trajectories stratified by use of cholesterol-lowering medications (row one) controlled for the effects of age, gender, educational attainment, smoking status,
systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index, and APOE allele status (n = 555). Cholesterol trajectories stratified according to APOE
allele status (row two) controlled for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet,
body mass index, and age of first using cholesterol-lowering medications. These trajectories only included subjects who had a history of using cholesterol-lowering
medications (n = 102). Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E.
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Figure 3. Cholesterol trajectories stratified according to gender, and APOE allele status adjusting for age of menopause, use of supplemental
estrogen, and cause of menses cessation.

Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes.
Cholesterol trajectories stratified according to gender (row one) controlled for the effects of age, educational attainment, smoking status, systolic and diastolic blood
pressure, blood sugar, use of cholesterol-lowering medications, restricted diet, body mass index, and APOE allele status (n = 555). Adjusted model controlled for the
effects of age, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, body mass index, restricted diet, APOE allele status, age of
menopause, use of supplemental estrogen, and cause of cessation of menses (n = 335). Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E.
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Figure 4. Cholesterol trajectories stratified according to longevity, and APOE allele status for subjects who lived beyond 80 years of age.

Notes: APOE e4+ includes subjects with e3/e4 or e4/e4 genotypes; e3 includes subjects with e3/e3 genotype; and e2+ includes subjects with e2/e2 or e2/e3 genotypes.
All models controlled for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass
index, and use of cholesterol-lowering medications. Longevity models (row 1) also controlled for the effects of APOE allele status Cholesterol trajectories according to
longevity (n = 555); cholesterol trajectories according to APOE allele status (n = 430); Abbreviations: HDL = high density lipoprotein; APOE = apolipoprotein E.

Int. J. Environ. Res. Public Health 2014, 11

10677

Table 2. Demographic characteristics of final sample (n = 596).
Characteristic
Avg. age, midlife (range, SD)
Gender, n (%)
Men
Women
Educational attainment
<High school
>High school
Smoking midlife, n (%), n = 577
Non-smoker
Former
Current
Smoking, late life, n (%), n = 585
Non-smoker
Former
Current
Use of cholesterol-lowering medications, n (%)
No
Yes
* Avg. age cholesterol medication use (SD, range)
Avg. midlife blood sugar, mg/dL (SD, range), n = 590
Avg. late life blood sugar, mg/dL (SD, range), n = 584
Avg. midlife systolic blood pressure, mmHg (SD, range)
Avg. late life systolic blood pressure, mmHg (SD, range), n = 588
Avg. midlife diastolic blood pressure, mmHg (SD, range)
Avg. late life diastolic blood pressure, mmHg (SD, range), n = 588
Avg. midlife body mass index, Kg/M2 (SD, range)
Avg. late life body mass index, Kg/M2 (SD, range), n = 588
** Supplemental estrogen, n (%)
No
Yes
Dietary restriction, n (%)
No
Yes
APOE allele status, n (%)
e2+
e3
e4+
Avg. number of cholesterol measures (range, SD)
Total cholesterol
HDL cholesterol

Value
38.3 (30.0–55.0, 5.5)
242 (40.6)
354 (59.4)
387 (66.2)
198 (33.8)
282 (48.9)
11 (1.9)
284 (49.2)
231 (39.5)
201 (34.3)
153 (26.1)
487 (81.7)
109 (18.3)
69.7 (45.0–88.0, 11.4)
79.4 (13.5, 51.0–173.0)
93.3 (24.2, 52.0–326.0)
128.4 (16.0, 90.0–195.0)
135.9 (19.5, 92.0–212)
81.3 (10.4, 50.0–125.0)
76.6 (9.8, 50.0–104.0)
25.1 (3.8, 15.4–41.2)
26.7 (4.3, 16.7–43.7
315 (89.0)
39 (11.0)
345 (57.9)
251 (42.1)
61 (10.2)
406 (68.1)
129 (21.6)
14.4 (4.0–19.0, 2.5)
5.1 (2.0–10.0, 1.8)

Notes: Midlife and late life were the 1st and 15th examinations, respectively; * The average age in which
subjects first reported using cholesterol-lowering medications; ** Supplemental estrogen use was
assessed in only women.
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Table 3. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol
ratio stratified according to APOE allele status.
Model
Unadjusted model
e2+
e3
e4+
Adjusted model
e2+
e3
e4+

Total Cholesterol
EDF
Adjusted R2
0.12
4.9
7.7
5.7
0.22
4.9
7.5
5.6

HDL Cholesterol
EDF
Adjusted R2
0.01
1.0
3.6
2.8
0.19
1.0
3.7
2.9

Total: HDL Cholesterol
EDF
Adjusted R2
0.06
3.8
4.4
3.3
0.20
3.7
4.7
3.3

Notes: Unadjusted model only included APOE allele status (n = 596); Adjusted model controlled
for the effects of age, gender, educational attainment, smoking status, systolic and diastolic blood
pressure, blood sugar, restricted diet, body mass index, and use of cholesterol-lowering
medications (n = 555); Abbreviations: EDF = effective degrees of freedom; HDL = high density
lipoprotein; APOE = apolipoprotein E.

In general, APOE e2+ subjects had higher HDL cholesterol levels compared to APOE e3 and APOE
e4+ subjects (Figure 1). APOE e2+ subjects displayed a gradual increase in HDL cholesterol from
midlife through late life, whereas HDL cholesterol declined until approximately 75 years of age,
which was followed by an increase in HDL cholesterol, for APOE e3 and APOE e4+ subjects.
The greatest difference in HDL cholesterol between APOE e2+, e3, and e4+ subjects was observed
between 75 and 80 years of age. A mixed-effects regression model that included linear, quadratic,
and cubic terms for age did not detect any statistically significant differences in these polynomial
terms according to APOE allele status. However, the linear (F-value = 6.6, p = 0.01) and cubic
(F-value = 21.1, p < 0.01) main effect polynomial terms were statistically significant.
All subjects maintained consistent total: HDL cholesterol ratio until 70 years of age when the
trajectories began to decline (Figure 1). APOE e2+ subjects maintained significantly lower total:
HDL ratios from midlife through late life compared to APOE e3 and APOE e4+ subjects and these
differences increased with advancing age. There were little to no differences in the trajectories of total:
HDL cholesterol ratio according to APOE allele status. A mixed-effects model that included linear
through quartic polynomial terms for age and interactions with APOE allele status detected a
statistically significant interaction between age and APOE allele status (F-value = 3.2, p = 0.04).
The respective interactions between APOE allele status and the other three polynomial terms were not
statistically significant.
3.3. Cholesterol Trajectories according to Use of Cholesterol-Lowering Medications
The trajectories of serum cholesterol levels stratified according to use of cholesterol-lowering
medications are presented in the first row of Figure 2. In general, subjects who had a history of taking
cholesterol-lowering medications had higher serum total cholesterol levels, lower HDL cholesterol
levels, and higher total: HDL cholesterol ratios from midlife through late life compared to subjects
who did not have a history of taking cholesterol-lowering medications. Subjects who had a history of
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using cholesterol-lowering medications had similar EDF values for total cholesterol, HDL cholesterol,
and total: HDL cholesterol ratio compared to non-medication users (Table 4). Medication users
maintained higher total cholesterol from midlife through 80 years of age, but these subjects had a
greater decline in total cholesterol following 60 years of age compared to non-medication users.
These apparent differences in the trajectories of serum total cholesterol are consistent with the results
of a mixed-effects model that included linear through 7th order polynomial terms for age. This model
detected statistically significant differences in the APOE allele status by linear (F-value = 22.2,
p < 0.01), quadratic (F-value, p = 0.04), and cubic (F-value = 4.7, p < 0.03) interaction terms.
Medication users had higher HDL cholesterol levels during midlife compared to non-medication
users. Medication users, however, did have a slight decline in HDL cholesterol until 80 years of age,
whereas non-medication users displayed a gradual increase until 60 years of age, which was followed
by a slight decline. Both medication users and non-users exhibited an increase in HDL cholesterol
levels following 80 years of age. These findings are supported by the results of a mixed-effects
regression model that included linear, quadratic, and cubic polynomial terms for age. There were
significant linear (F-value = 6.7, p = 0.01) and cubic trends (F-value = 21.1, p < 0.01) in HDL
cholesterol according to age for all subjects, but only the APOE allele status by age interaction term
was statistically significant (F-value = 7.9, p = 0.01).
Finally, subjects with a history of using cholesterol-lowering medications maintained significantly
higher total: HDL cholesterol ratio compared to non-medication users from midlife through late life
(row 1, Figure 2). However, medication users did have a greater decline in total: HDL cholesterol ratio
following 70 years of age. This is supported by the findings of a mixed-effects regression model that
included linear, quadratic, and cubic polynomial terms for age. In this model the age2 by APOE allele
status interaction term was statistically significant (F-value = 7.6, p = 0.01).
The second row of Figure 2 presents cholesterol trajectories according to APOE allele status
adjusting for the effects of age of first using cholesterol-lowering medications. APOE e2+, e3,
and e4+ subjects had similar trajectories of serum total cholesterol through 50 years of age.
Total cholesterol continued to increase among APOE e4+ subjects until 60 years of age, whereas total
cholesterol began to decline at 50 years of age for APOE e3 and APOE e2+ subjects. The EDF values
for the smooth terms were similar for APOE e4+, e3, and e2+ subjects (Table 3). However, a mixed-effects
model that included linear through quartic polynomial terms for age detected statistically significant
differences in the quadratic (F-value = 3.3, p = 0.04) and quartic (F-value = 9.6, p < 0.01) polynomial
terms according to APOE allele status while the cubic interaction term approached statistical
significance (F-value = 2.5, p = 0.08).
APOE e4+ had significantly higher HDL cholesterol levels during midlife compared to APOE e3
and APOE e2+ subjects (row two, Figure 2). APOE e4+ subjects, however, did exhibit the greatest
decline in HDL cholesterol with age. According to the EDF values for the smooth terms APOE e4+
and APOE e2+ subjects displayed linear declines in HDL cholesterol, whereas the trajectory of HDL
cholesterol for APOE e3 subjects showed a slight quadratic trend (Table 4). There was considerable
overlap in the 95% confidence intervals for the estimated values of HDL cholesterol, which suggests
there is not a significant difference in the trajectories of HDL cholesterol according to APOE allele
status. This is supported by the results of a mixed-effects regression model that included linear and
quadratic polynomial terms for age interactions with APOE allele status. In this model, the linear term
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for age was statistically significant (F-value = 16.2, p < 0.01), but there was not a statistically
significant interaction between age and APOE allele status.
There was substantial overlap in the 95% confidence intervals for estimated values of total:
HDL cholesterol ratio according to APOE e4 allele status (row two, Figure 2). Based on the EDF
values for the smooth terms (Table 4), APOE e4+ and e3 subjects exhibited cubic trends in total:
HDL cholesterol ratio. APOE e3 and APOE e4+ subjects maintained consistent total: HDL cholesterol
ratio until 70 years of age, at which point the trajectories began to decline. The total: HDL cholesterol
ratio trajectory for APOE e2+ subjects followed a quartic trajectory (Table 4). The ratio of total:
HDL cholesterol increased from 45–55 years of age, decreased until 60 years of age, plateaued until
75 years of age, and declined dramatically after 75 years of age. These visibly evident differences in
total: HDL cholesterol ratio trajectories according to APOE allele status are supported by the results of
a mixed-effects regression model that included linear through quartic polynomial terms for age in
which the age4 by APOE allele status interaction was the only statistically significant interaction term
(F-value = 3.5, p = 0.03).
Table 4. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol
ratio stratified according to use of cholesterol lowering medications, and APOE allele
status adjusting for age of first using cholesterol lowering medications.
Model
Use of cholesterol-lowering
medications
No
Yes
Adjusted model
e2+
e3
e4+

Total Cholesterol
EDF Adjusted R2

HDL Cholesterol
EDF
Adjusted R2

0.22
7.2
5.4

0.19
3.7
2.5

0.26
3.4
4.6
4.6

Total: HDL Cholesterol
EDF
Adjusted R2
0.16
4.0
3.7

0.28
1.0
1.5
1.0

0.20
3.8
3.3
2.6

Notes: Model for use of cholesterol-lowering medications controlled for the effects of gender, educational
attainment, smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index,
and APOE allele status (n = 555). Adjusted model controlled for the effects of age, gender, educational attainment,
smoking status, systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index,
APOE allele status, and age of first using cholesterol-lowering medications (n = 102). Abbreviations:
EDF = effective degrees of freedom; HDL = high density lipoprotein; APOE = apolipoprotein E.

3.4. Cholesterol Trajectories Stratified by Gender, and APOE Allele Status Adjusting for Menopause
Cholesterol trajectories stratified according to gender are presented in the first row of Figure 3.
During midlife, women had significantly higher total cholesterol levels compared to men, but women
exhibited an increase in total cholesterol until 55 years of age compared to 45 years of age for men.
The EDF values were similar for men and women, but women showed a greater decline in serum total
cholesterol with age compared to men. These findings are supported by the results from a
mixed-effects regression model that included linear through 7th order polynomial terms for age and
interactions terms with APOE allele status. This model detected statistically significant differences in
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the linear (F-value = 149.6, p < 0.01), quadratic (F-value = 35.5, p < 0.01), quartic (F-value = 43.0,
p < 0.01), and quintic (i.e., age5; F-value = 9.3, p < 0.01) polynomial terms according to APOE
allele status.
Both men and women maintained consistent levels of HDL cholesterol (first row, Figure 3; Table 5).
Women had significantly higher HDL cholesterol levels from midlife through late life compared to
men. The estimated trajectories for HDL cholesterol and the EDF values indicate that there is a
between group effect of sex on HDL cholesterol, but that the trajectories do not differ according to sex.
A mixed-effects model that included linear, quadratic, and cubic polynomial terms for age along with
interactions with APOE allele status supports this finding. There were no significant differences in any
of the polynomial terms included in this model according to APOE allele status.
Finally, men maintained significantly higher total: HDL cholesterol ratio compared to women from
midlife through late life (first row, Figure 3). The EDF values for the smooth terms were very similar
for men and women, but there is evidence for significant differences in these trajectories.
A mixed-effects model that included linear through quartic polynomial terms for age detected
statistically significant differences in the linear interaction term (F-value = 6.6, p = 0.01) and the
quadratic interaction term approached statistical significance (F-value = 3.6, p = 0.06).
Table 5. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol
ratio according to gender, and APOE allele status adjusting for age of menopause.
Model
Gender
Male
Female
Adjusted
e2+
e3
e4+

Total Cholesterol
EDF
Adjusted R2
0.25
6.2
7.3
0.25
5.0
7.1
5.5

HDL Cholesterol
EDF
Adjusted R2
0.19
3.0
4.2
0.08
1.0
4.2
2.6

Total: HDL Cholesterol
EDF
Adjusted R2
0.20
4.5
4.3
0.15
2.9
4.6
3.1

Notes: Model for gender controlled for the effects of educational attainment, smoking history,
average systolic and diastolic blood pressure, average blood sugar, restricted diet, average body
mass index, use of cholesterol-lowering medications, and APOE allele status (n = 555). Adjusted
model controlled for the effects of educational attainment, smoking, systolic and diastolic
blood pressure, blood sugar, restricted diet, body mass index, APOE allele status, age of
menopause, use of supplemental estrogen, and cause of cessation of menses (n = 335).
Abbreviations: EDF = effective degrees of freedom; HDL = high density lipoprotein;
APOE = apolipoprotein E.

Cholesterol trajectories stratified according to APOE allele status among women adjusted for the
effects of supplemental estrogen, age of menopause, and cause of menses cessation are presented in
the second row of Figure 3. The EDF values for the smooth terms are provided in Table 5.
Women who were APOE e2+ maintained significantly lower total cholesterol and total: HDL
cholesterol ratio from midlife through late life compared to women who were APOE e4+ or APOE e3.
However, mixed-effects models for total cholesterol, which included linear through 7th order
polynomial terms for age, and total: HDL cholesterol ratio, which included linear through quartic
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polynomial terms for age, did not detect statistically significant differences in these trajectories
according to APOE allele status. All women maintained consistent levels of HDL cholesterol and there
were little to no differences in HDL cholesterol according to APOE allele status from midlife through
late life. These findings are consistent with those from a mixed-effect model that did not detect
any statistically significant differences in linear through quartic polynomial terms according to
APOE allele status.
3.5. Cholesterol Trajectories Stratified according to Longevity
An explanation for the observed decline in total cholesterol levels, increase in HDL cholesterol
levels and decline in total: HDL cholesterol ratio is that subjects with healthy cholesterol levels are
more likely to reach very old age. The majority of subjects included in the final sample lived beyond
80 years of age (n = 460, 77.2%), which included 133 subjects who lived past 90 years of age.
Compared to subjects who did not live beyond 80 years of age, subjects who were 80 years of age or
older were more likely to be female (n = 290 (63.0%), n = 64 (47.1%),
= 11.1, p < 0.01),
and less likely to have been a smoker during midlife (n = 95 (72.5%), n = 189 (42.4%), = 37.8,
p < 0.01) and late life (n = 57 (43.8%), n = 96 (21.1%), = 30.7, p < 0.01).
Since there were statistically significant differences in the characteristics of the final sample
according to longevity, a subsequent analysis was conducted in which the trajectories of total
cholesterol, HDL cholesterol, and total: HDL cholesterol were stratified according to longevity
(age of death < 80 years, >80 to <90, and >90). These models adjusted for the effects of age,
educational attainment, smoking, systolic and diastolic blood pressure, blood sugar, BMI, restricted
diet, and use of cholesterol-lowering medications.
The trajectories for total cholesterol, HDL cholesterol, and total: HDL cholesterol ratio are
presented in the first row of Figure 4 and the corresponding EDF values are presented in Table 6.
Subjects who lived beyond 90 years of age had the lowest total cholesterol levels during midlife,
but the highest levels for total cholesterol during old age. Compared to subjects who did not live
beyond 80 years, subjects who lived between 80 and 90 years had similar total cholesterol levels
during midlife and slightly higher total cholesterol levels, most notably after 70 years of age.
The serum total cholesterol trajectories according to longevity were examined further with a
mixed-effects model that included linear through 7th order polynomial terms with age and interactions
according to longevity status. This model detected statistically significant interactions between longevity
and the linear (F-value = 21.7, p < 0.01), quadratic (F-value = 6.3, p < 0.01), quartic (F-value = 5.0,
p = 0.01), and quintic (F-value = 9.2, p < 0.01) polynomial terms.
There were little to no differences in the estimated trajectories of HDL cholesterol according to
longevity. This is supported by the findings from a mixed-effects model that included linear, quadratic,
and cubic polynomial terms for age and interactions with longevity status. In this model, the cubic
polynomial term was statistically significant (F-value = 20.6, p < 0.01), but there was not a statistically
significant interaction between age3 and longevity.
Finally, subjects who did not live past 80 years had a linear decline in total: HDL cholesterol ratio,
whereas total: HDL cholesterol ratio for subjects who lived past 80 and 90 years of age did not begin
to decline until approximately 65 years of age. Interestingly, subjects who lived past 90 years of age
had low total: HDL cholesterol ratio that increased until approximately 60 years of age. This visibly
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apparent difference in the trajectory of total: HDL cholesterol ratio is detected in a mixed-effects
model that included linear, quadratic, and cubic terms for age in which the interaction term between
age2 and longevity was statistically significant (F-value = 3.0, p = 0.05).
Table 6. EDF and adjusted R2 for trajectories of total, HDL, and total: HDL cholesterol
ratio according to longevity, and APOE allele status among long-lived subjects.
Model
Longevity
<80
>80 to <90
>90
APOE allele status
e2+
e3
e4+

Total Cholesterol
EDF
Adjusted R2
0.22
5.3
6.8
6.7
0.22
5.0
7.3
5.8

HDL Cholesterol
EDF
Adjusted R2
0.19
3.1
3.6
1.0
0.16
1.0
2.1
1.0

Total: HDL Cholesterol
EDF
Adjusted R2
0.20
1.0
4.0
3.3
0.16
3.2
3.8
3.1

Notes: All models controlled for the effects of age, gender, educational attainment, smoking status,
systolic and diastolic blood pressure, blood sugar, restricted diet, body mass index, and use of
cholesterol-lowering medications. Longevity models also controlled for the effects of APOE allele
status; Cholesterol trajectories according to longevity (n = 585); cholesterol trajectories according
to APOE allele status (n = 430).

A final analysis limited to the 460 subjects who lived beyond 80 years of age (77% of final sample)
was conducted to assess if trajectories of total cholesterol, HDL cholesterol, and total: HDL cholesterol
ratio according to APOE allele status differed once subjects who did not live beyond 80 years were
removed. These models adjusted for the effects of age, educational attainment, smoking history,
average systolic and diastolic blood pressure, average blood sugar, average BMI, restricted diet, and
use of cholesterol-lowering medications. It should be noted that APOE e3 subjects remained in the
FHS Original Cohort longer compared to APOE e2 and APOE e4 subjects as indicated by the five
more years of observation for APOE e3 subjects (Figure 4). There were minimal differences in the
trajectories and EDF values of total cholesterol, HDL cholesterol, and total: HDL cholesterol ratio
(second row, Figure 4; Table 6) compared to the trajectories and EDF values that included all subjects
in the analysis (second row, Figure 1; Table 3). The findings from the mixed-effects models for these
trajectories were also consistent with the models that included the entire sample. The mixed-effects
model for total cholesterol detected statistically significant interactions between APOE allele status
and the quadratic (F-value = 5.1, p = 0.01) and quartic (F-value = 6.6, p = 0.01) polynomial terms
for age. As was observed in the initial analysis, there were no statistically significant interactions
between any of the polynomial terms for age and APOE allele status in the mixed-effects model
for HDL cholesterol. Finally, the mixed-effects model of total: HDL cholesterol for subjects who lived
beyond 80 years of age detected a statistically significant interaction between age and APOE allele
status (F-value = 4.2, p = 0.02), whereas the interactions between APOE allele status and other polynomial
terms (quadratic, cubic, and quartic) were not statistically significant. This is consistent with the results
from the mixed-effects model that included the entire final sample. To summarize, these findings provide
evidence that the results from the initial analysis are not due to a healthy survivor bias.
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4. Discussion
The findings from this study present new evidence for age related changes in total cholesterol,
HDL cholesterol, and total: HDL cholesterol ratio according to APOE allele status. Results from the
GAMMs indicated that APOE e2+ subjects maintained lower serum total cholesterol levels,
higher HDL cholesterol levels, and lower total: HDL cholesterol ratios from midlife through late life
compared to APOE e3 and APOE e4+ subjects after controlling for the effects of age gender,
educational attainment, smoking, use of cholesterol-lowering medications, systolic and diastolic blood
pressure, blood sugar, diet restriction, and BMI. Similar findings were observed when subjects who did
not live beyond 80 years of age were excluded. Further analysis using mixed-effects regression models
detected statistically significant interactions between polynomial terms for age and APOE allele status
for trajectories of serum total cholesterol. This provides evidence that trajectories of serum total
cholesterol from midlife through late life differ according to APOE allele status. However, a mixed-effects
regression model for HDL cholesterol did not detect any statistically significant interactions between
APOE allele status and polynomial terms for age. This suggests that there is a between group effect for
APOE on HDL cholesterol levels, but there are not substantial differences in HDL cholesterol
trajectories according to APOE allele status. Finally, there was a statistically significant interaction
between age and APOE allele status in the mixed-effects model for total: HDL cholesterol ratio,
but the interactions between APOE allele status and quadratic, cubic, and quartic polynomial terms
were not statistically significant. These findings, when interpreted with the results from the GAMM,
indicate there is a significant between group effect for APOE allele status on total: HDL cholesterol
trajectories and that APOE e2+ subjects have a greater overall decline in total: HDL cholesterol ratio
than APOE e3 or APOE e4+ subjects.
Prior research has focused on age-related changes to total and HDL cholesterol levels through the
lifespan and the present analysis is the first study to our knowledge that has examined trajectories of
serum cholesterol from midlife through late life stratified according to APOE allele status. In the
current study, serum total cholesterol levels increased with age during midlife but declined during old
age. These results are consistent with other studies that have examined age related changes in serum
total cholesterol [19–22,24,25]. We observed an increase in HDL cholesterol from midlife through late
life, but there were no statistically significant differences in HDL cholesterol trajectories according
to APOE allele status. This increasing trend in HDL cholesterol with age as been reported
previously [25], but other studies have observed consistent levels [22] or a decline [20] in
HDL cholesterol with age.
Previous studies have also assessed sex differences in serum cholesterol levels. The findings from
the GAMM and mixed-effects models provide evidence for significant differences in the trajectories of
serum cholesterol between men and women. Women had lower serum total cholesterol during midlife,
but higher total cholesterol during late life compared to men. Women also had significantly higher
HDL cholesterol and total HDL cholesterol and lower total: HDL cholesterol ratio from midlife
through late life compared to men. These results are consistent with previous research [31,76].
It should be noted that we chose not to stratify all analyses according to sex because sex differences in
the trajectories of serum cholesterol levels according to APOE allele status were not the objective of
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the present analysis. Future research should examine how sex may modify the relationship between
APOE allele status and trajectories of serum cholesterol levels from midlife through late life.
The decline in total cholesterol with increasing age among older adults observed in the current
study may be the result of a survivor effect in which subjects at an increased risk for mortality due to
diseases caused by elevated cholesterol die and subjects with healthy cholesterol levels remain in a
study into old age [77]. In the current study, subjects who lived beyond 90 years had lower total
cholesterol during midlife, but higher total cholesterol during late life, compared to subjects who lived
between 80 and 90 years. Subjects who lived between 80 and 90 years had higher total cholesterol
levels during late life compared to subjects who did not live past 80 years, but there were little to no
differences in midlife total cholesterol levels between these two groups. There is evidence from
previous research that a decrease in cholesterol synthesis by the liver and a decline in the amount
of dietary cholesterol absorbed by the intestines contributes to the decline in total cholesterol later in
life [78–80]. A survivor effect may also partially explain the increase in HDL cholesterol after
80 years of age. Subjects who lived beyond 80 years of age were more likely to be female and less
likely to smoke during midlife and late life. These characteristics have been associated with higher
levels of HDL cholesterol [39] and the overall better health of subjects who lived past 80 years may
explain the increase in HDL cholesterol among the oldest-old in the FHS Original Cohort.
Certain limitations in this study need to be acknowledged. First, we limited the number of
covariates included in the adjusted models by using midlife and late life values for potentially
important covariates such as smoking status, measures for systolic and diastolic blood pressure and
blood sugar, use of cholesterol-lowering medications, and BMI. This approach allowed us to account
for changes in these covariates from midlife through late life, but may have oversimplified
the relationship between these variables and trajectories of serum cholesterol levels. Furthermore,
we controlled for the use of cholesterol-lowering medications by dichotomizing subjects as ever using
medications (yes, no). It has been suggested that adding a constant value to observed values for
subjects receiving treatment is more appropriate when controlling for treatment effects than including
treatment status as a dichotomous covariate [81]. These limitations can be addressed by future research
that focuses on how changes in specific health behaviors and health conditions through the life span
influence trajectories of serum cholesterol from midlife through late life. A second potential limitation
is that the FHS did not provide a definition for what constituted a restricted diet. Clinical trials indicate
that diets rich in whole grains, fruits, nuts, and vegetables have beneficial effects on cardiovascular
disease risk factors including high cholesterol, diabetes, and hypertension [82]. We were unable to
assess the dietary preferences and caloric intake among subjects who reported consuming a restricted
diet because the FHS did not introduce a detailed food history questionnaire until the 20th clinical
examination. Only 71 subjects (11.9%) included in the final sample were still remaining in the FHS
Original Cohort during the 20th examination and controlling for the effects of dietary preferences and
caloric intake would have considerably reduced the sample size. Therefore, our findings need to be
replicated using other sample populations from studies that have assessed caloric intake throughout the
life span since older adults can experience decreased appetite [83] and malnutrition [84], which may
contribute to a decline in cholesterol during old age. Another limitation of the present analysis is we
did not control for potentially important factors that modify or are related to serum cholesterol levels such
as alcohol consumption [85], physical activity [86], cardiovascular diseases [87], and inflammation [88].
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Additional research on the effects that these variables, as well as other genetic, biological, lifestyle,
and sociocultural factors, have on serum cholesterol levels through the life span is warranted.
5. Conclusions
In summary, this study presents evidence that serum total cholesterol and total: HDL cholesterol
ratio trajectories from midlife through late life differ according to APOE allele status. Between-group
differences in HDL cholesterol according to APOE allele status were also detected.
The findings from this study have important implications to public health. First, we observed that
adults who lived past 90 years of age had higher total cholesterol during late life compared to adults
who did not live past 80 or 90 years of age. This has potentially important implications for the
treatment of high cholesterol with statins and other cholesterol-lowering medications because these
findings suggest that higher cholesterol may be associated with longevity. An argument can be made
that it may be harmful to prescribe older adults statins or other medications to lower cholesterol based
on evidence that low serum cholesterol and a decline in serum cholesterol are associated with
increased mortality [89,90]. However, it is not clear if a decline in cholesterol plays a causal role in
mortality or this decline is a consequence of changes to systems involved in cholesterol homeostasis,
such as liver function, cholesterol metabolism, and appetite, that are negatively affected by biological
changes that occur during the period of terminal decline prior to death [91]. Second, the APOE e4
allele is associated with an increased risk for several aging related diseases, including AD [54] and
cardiovascular diseases [92], whereas the APOE e2 allele has been associated with a decreased risk for
these diseases [55]. To efficiently modify cholesterol, and as a result, disease risk, it is necessary to
take into account APOE allele status and how APOE allele status influences serum cholesterol levels
from midlife through late life. A plausible hypothesis is that the increased risk for cognitive and
vascular diseases among older adults who carry one or more APOE e4 alleles may be due, in part,
to higher total cholesterol and lower HDL cholesterol from midlife through late life, whereas the
decreased risk for these diseases associated with the APOE e2 allele may be due to the lower total
cholesterol and higher HDL cholesterol across the life span. This hypothesis is based on interpreting
the findings of the present analysis within the context of findings from previous research. Additional
research is necessary to determine if reducing total cholesterol and increasing HDL cholesterol
decreases the risk for cognitive and vascular diseases among adults who carry one or more
APOE e4 alleles.
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